Does CyberAgent invest in startups?
Yes, Cytokinetics has received FDA approval for its drug MYQORZO (aficamten). The drug was approved in late 2025 for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Following its U.S. approval, the drug was also cleared for use by the China National Medical Products Administration in December 2025, and it has received positive recommendations for marketing authorization in the European Union. This approval marks a major milestone for the company, establishing its leadership in muscle biology research and providing a new therapeutic option for patients suffering from this condition.
Related FAQs
Cytokinetics, Incorporated is a prominent, publicly traded biopharmaceutical enterprise headquartered in South San Francisco, California, focusing on the discovery and development of muscle activators and novel treatments for cardiovascular and ne...
CyberAgent, a prominent Japanese technology and media firm, generally receives positive marks from employees regarding its company culture and work-life balance.
CyberAgent maintains a clear commitment to ethical research and corporate responsibility, aiming to use technology for the advancement of society.
Yes, CyberAgent is heavily involved in artificial intelligence research and development.